 |
|
The Response of Diabetic Retinopathy to 41 Months of Multiple Insulin Injections, Insulin Pumps, and Conventional Insulin Therapy
Olaf Brinchmann-Hansen, MD;
Knut Dahl-Jørgensen, MD;
Kristian F. Hanssen, MD;
Leiv Sandvik, MSc
Arch Ophthalmol. 1988;106(9):1242-1246.
Abstract
• Forty-five diabetic patients were randomized and treated with continuous subcutaneous insulin infusion (CSII), multiple insulin injections (MI), or conventional insulin treatment (CIT) for 41 months. Near-normoglycemia was obtained with CSII and MI but not with CIT. A transient increase in microaneurysms and hemorrhages was seen at three months in CSII-treated patients. After 41 months, a moderate progression in microaneurysms and hemorrhages was registered, as assessed from fundus photographs, in all treatment groups. Fluorescein angiograms indicated a tendency (not statistically significant) to retarded progression of retinopathy in MI- and CSII-treated patients compared with CIT-treated patients. Soft exudates developed after three to six months of rapid tightening of metabolic control in 50% of patients on CSII and MI regimens. Those patients who had soft exudates had a slower progression of retinopathy three years later than those who did not develop soft exudates. Transient progression of retinopathy may be related to fluctuations in blood glucose levels, although a favorable effect of long-term improved metabolic control was not documented.
Author Affiliations
From the Department of Ophthalmology, Ullev l University Hospital (Dr Brinchmann-Hansen); the Departments of Medicine B (Dr Hanssen) and Pediatrics (Dr Dahl-Jørgensen), Aker University Hospital; and the Medstat-Center for Medical Statistics (Mr Sandvik), Oslo.
Footnotes
Accepted for publication March 1, 1988.
Reprint requests to Department of Ophthalmology, Ullevl University Hospital, Kirkeveien 166, 0407 Oslo 4, Norway (Dr Brinchmann-Hansen).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Risk of Developing Retinopathy in Diabetes Control and Complications Trial Type 1 Diabetic Patients With Good or Poor Metabolic Control
Zhang et al.
Diabetes Care 2001;24:1275-1279.
ABSTRACT
| FULL TEXT
Interpretation of Hemoglobin A1c (HbA1c) Values among Diabetic Patients: Implications for Quality Specifications for HbA1c
Skeie et al.
Clin. Chem. 2001;47:1212-1217.
ABSTRACT
| FULL TEXT
Early Worsening of Diabetic Retinopathy in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Resea
Arch Ophthalmol 1998;116:874-886.
ABSTRACT
| FULL TEXT
The Treatment of Diabetic Retinopathy: A View for the Internist
Raskin and Arauz-Pacheco
ANN INTERN MED 1992;117:226-233.
ABSTRACT
Screening for Diabetic Retinopathy
Singer et al.
ANN INTERN MED 1992;116:660-671.
ABSTRACT
|
